Waltham, Massachusetts, based Tesaro (TSRO), is an oncology-focused biopharma company, which develops and commercializes effective therapeutics for cancer patients. The company aims to leverage its experience to identify, acquire, and develop promising drug candidates as well as commercialize them for the treatment of cancer patients. It in-licenses these products rather than perform in-house drug discovery. TSRO has seen a growth of more than 100% since the beginning of this year.
The second-half of 2013 will be more important from investors' perspective, as I expect Tesaro's first Phase 3 data readout, that includes Rolapitant data for prevention of chemotherapy induced nausea and vomiting, or CINV. With Niraparib gaining more visibility as PARP inhibitor...
Only subscribers can access this article, which is part of the PRO research library covering 3,577 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: